Ovid CEO Jeremy Levin chides pharma for using tax savings for buybacks, not R&D

6th June 2018 Uncategorised 0

Big Pharma authorized tens of billions of dollars’ worth of share buybacks before or shortly after tax reform, and that irked Ovid chief Jeremy Levin. At BIO this week, the industry veteran said upping R&D spending would have been a better investment.

More: Ovid CEO Jeremy Levin chides pharma for using tax savings for buybacks, not R&D
Source: fierce